PURPOSE OF REVIEW: This article describes the clinical characteristics, diagnosis, molecular pathogenesis, and treatment of facioscapulohumeral muscular dystrophy (FSHD). RECENT FINDINGS: FSHD comprises two genetically distinct types that converge on a common downstream pathway of the expression of the toxic protein DUX4. Approximately 95% of patients have FSHD type 1 (FSHD1), in which loss of DNA repetitive elements (D4Z4 repeats) in the subtelomeric region of chromosome 4q causes decreased methylation and epigenetic derepression of DUX4, a gene contained within each D4Z4 repeat. FSHD type 2 (FSHD2) occurs through a deletion-independent mechanism but, similar to FSHD1, leads to decreased methylation and epigenetic derepression in the same region of chromosome 4q. Whereas FSHD1 is dominantly inherited, FSHD2 shows digenic inheritance, and about 80% of patients will have a mutation in the SMCHD1 gene. DUX4 lacks a polyadenylation signal, so both FSHD1 and FSHD2 only occur in the presence of permissive 4q polymorphisms, which provide a stabilizing polyadenylation sequence. FSHD is an epigenetic disease, and penetrance and severity are related to both the number of residual D4Z4 units and D4Z4 methylation. SUMMARY: Recent consensus guidelines outline standards for care for FSHD, and identification of potential therapeutic targets have shifted emphasis in the research community toward drug development and clinical trial planning.
PURPOSE OF REVIEW: This article describes the clinical characteristics, diagnosis, molecular pathogenesis, and treatment of facioscapulohumeral muscular dystrophy (FSHD). RECENT FINDINGS:FSHD comprises two genetically distinct types that converge on a common downstream pathway of the expression of the toxic protein DUX4. Approximately 95% of patients have FSHD type 1 (FSHD1), in which loss of DNA repetitive elements (D4Z4 repeats) in the subtelomeric region of chromosome 4q causes decreased methylation and epigenetic derepression of DUX4, a gene contained within each D4Z4 repeat. FSHD type 2 (FSHD2) occurs through a deletion-independent mechanism but, similar to FSHD1, leads to decreased methylation and epigenetic derepression in the same region of chromosome 4q. Whereas FSHD1 is dominantly inherited, FSHD2 shows digenic inheritance, and about 80% of patients will have a mutation in the SMCHD1 gene. DUX4 lacks a polyadenylation signal, so both FSHD1 and FSHD2 only occur in the presence of permissive 4q polymorphisms, which provide a stabilizing polyadenylation sequence. FSHD is an epigenetic disease, and penetrance and severity are related to both the number of residual D4Z4 units and D4Z4 methylation. SUMMARY: Recent consensus guidelines outline standards for care for FSHD, and identification of potential therapeutic targets have shifted emphasis in the research community toward drug development and clinical trial planning.
Authors: Richard J L F Lemmers; Jelle J Goeman; Patrick J van der Vliet; Merlijn P van Nieuwenhuizen; Judit Balog; Marianne Vos-Versteeg; Pilar Camano; Maria Antonia Ramos Arroyo; Ivonne Jerico; Mark T Rogers; Daniel G Miller; Meena Upadhyaya; Jan J G M Verschuuren; Adolfo Lopez de Munain Arregui; Baziel G M van Engelen; George W Padberg; Sabrina Sacconi; Rabi Tawil; Stephen J Tapscott; Bert Bakker; Silvère M van der Maarel Journal: Hum Mol Genet Date: 2014-09-25 Impact factor: 6.150
Authors: Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott Journal: Dev Cell Date: 2011-12-29 Impact factor: 12.270
Authors: C A Payan; J Y Hogrel; E H Hammouda; L Lacomblez; G Ollivier; V Doppler; B Eymard; S Attarian; J Pouget; C Desnuelle; P Laforêt Journal: Arch Phys Med Rehabil Date: 2009-07 Impact factor: 3.966
Authors: Abhijit Dandapat; Darko Bosnakovski; Lynn M Hartweck; Robert W Arpke; Kristen A Baltgalvis; Derek Vang; June Baik; Radbod Darabi; Rita C R Perlingeiro; F Kent Hamra; Kalpna Gupta; Dawn A Lowe; Michael Kyba Journal: Cell Rep Date: 2014-08-28 Impact factor: 9.423
Authors: Carlo Pietro Trevisan; Ebe Pastorello; Mario Armani; Corrado Angelini; Giovanni Nante; Giuliano Tomelleri; Paola Tonin; Tiziana Mongini; Laura Palmucci; Giuliana Galluzzi; Rossella G Tupler; Agata Barchitta Journal: Eur Neurol Date: 2006-06-27 Impact factor: 1.710
Authors: Richard J L F Lemmers; Patrick J van der Vliet; Jeroen P Vreijling; Don Henderson; Nienke van der Stoep; Nicol Voermans; Baziel van Engelen; Frank Baas; Sabrina Sacconi; Rabi Tawil; Silvère M van der Maarel Journal: Hum Mol Genet Date: 2018-10-15 Impact factor: 6.150
Authors: Richard J L F Lemmers; Nienke van der Stoep; Patrick J van der Vliet; Steven A Moore; David San Leon Granado; Katherine Johnson; Ana Topf; Volker Straub; Teresinha Evangelista; Tahseen Mozaffar; Virginia Kimonis; Natalie D Shaw; Rita Selvatici; Alessandra Ferlini; Nicol Voermans; Baziel van Engelen; Sabrina Sacconi; Rabi Tawil; Meindert Lamers; Silvère M van der Maarel Journal: J Med Genet Date: 2019-06-26 Impact factor: 6.318
Authors: Allison Ducharme-Smith; Stefan Nicolau; C Anwar A Chahal; Kirstie Ducharme-Smith; Shujah Rehman; Keerthi Jaliparthy; Nadeem Khan; Christopher G Scott; Erik K St Louis; Teerin Liewluck; Virend K Somers; Grace Lin; Peter A Brady; Margherita Milone Journal: Front Neurol Date: 2021-05-24 Impact factor: 4.003